8 research outputs found
Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure
Background Many reports have suggested that intermittent milrinone
infusion (IMI) may be efficacious in the management of end-stage
congestive heart failure (CHF), but this issue has not been clearly
established. The aim of our study was to investigate the effectiveness
of IMI in hospitalized patients with severe CHF undergoing long-term (4
months) post-therapy hemodynamics.
Methods Thirty-six patients (28 men, 8 women; mean age 65.6 +/- 8.2
years old) with end-stage CHF (New York Heart Association functional
class Ill-IV) were studied. Each patient received 4 cycles of 3 days per
week with milrinone therapy. Each cycle consisted of a loading dose of
50 mu g/kg over 10 minutes and a 72-hour continuous infusion of 0.5 mu
g/kg per minute under close monitoring. Hemodynamic changes were
determined during the first and fourth cycles and on 4-month
reexamination. Full clinical examination was performed at the beginning
(baseline) and at the end of 4-month follow-up.
Results The values of mean pulmonary arterial pressure, pulmonary
capillary wedge pressure, systemic vascular resistance, and pulmonary
vascular resistance were significantly decreased (P <.01) and cardiac
index was significantly increased (P < .01) compared with the baseline
of first and fourth cycles. At the end of the 4-month follow-up period
all hemodynamic parameters sustained the improvement. Clinical
examination at the end of the 4-month period showed that 21 (58.3%) of
36 patients remained in New York Heart Association functional class IV
but were hemodynamically improved, 13 (36.2%) of 36 were in functional
class III, and 2 (5.5%) of 36 were in class II-III. There were no
deaths during the study period.
Conclusions Our findings suggest that IMI in hospitalized patients with
severe CHF is hemodynamically efficacious. This beneficial hemodynamic
effect is maintained for at least 4 months after discontinuation of
therapy. These promising results raised the possibility that given
appropriately, milrinone may have an important role in end-stage CHF
Elevated plasma immunoreactive leptin levels preexist in healthy offspring of patients with essential hypertension
Background Plasma leptin levels and plasma insulin levels have been found to be elevated in patients with essential hypertension (EH) and have been suggested to be components of the metabolic syndrome. Increased heart rate (HR) may predict the development of EH in normal or borderline-hypertensive individuals. The aim of our study was to test the hypothesis that elevated plasma leptin and insulin levels as well as systolic blood pressure (SBP) and diastolic blood pressure (DBP) and increased resting HR preexist in the healthy offspring of patients with EH. Methods and Results Twenty-six (12 male, 14 female) healthy offspring of hypertensive patients, mean age 16 +/- 2.5 years and body mass index (BMI) of 21.5 +/- 2.8 kg/m(2) (group A), and 30 (14 mole, 16 female) healthy offspring of normotensive patients, mean age 17 +/- 2.3 years and BMI of 21.9 +/- 2.4 kg/m(2) (group B), were studied. (The two groups were matched for sex, age, and BMI). Mean SEP, DBP, resting HR, plasma leptin, and plasma insulin levels (radioimmunoassay method) were determined in the whole study population. Mean SEP, DBP, and resting HR were significantly higher in group A than in group B (120 +/- 12 vs 112 +/- 9.5 mm Hg, 77 +/- 9 vs 72 +/- 7 mm Hg, 79 +/- 8 vs 75 +/- 5 beats/min, P < .01, P < .05, and P < .05, respectively). Plasma leptin and insulin levels were significantly higher in group A than in group B (9 +/- 5.06 vs 5.6 +/- 2.5 ng/ml and 20.11 +/- 11.3 vs 14.8 +/- 5.2 mu IU/ml, P < .01 and P < .05, respectively). Conclusions Our findings support the hypothesis that hyperleptinemia, hyperinsulinemia, and elevated blood pressure and resting HR preexist in the healthy offspring of patients with EH
Fibrinolytic/hemostatic variables in arterial hypertension: Response to treatment with irbesartan or atenolol
Essential hypertension is often accompanied by abnormalities of the coagulation/fibrinolytic system, predisposing to a procoagulant state. The aim of the present study was to compare the effects of atenolol (beta(1)-blocker agent) and irbesartan (angiotensin II type 1 receptor antagonist) on plasma levels of hemostatic/fibrinolytic and endothelial function markers in a cohort of previously untreated hypertensives. Fifty-four patients were randomly assigned to atenolol 25 to 150 mg (26 patients) or irbesartan 75 to 300 mg (28 patients). The plasma levels of plasminogen activator inhibitor-1 antigen, thrombomodulin, tissue factor pathway inhibitor antigen, fibrinogen, and factor XII were determined before and after 6 months of therapy. Age, gender distribution, body mass index, lipid profile, and baseline values of the measured markers were similar in both groups. Baseline values for systolic and diastolic blood pressure, as well as the reduction after treatment, were not significantly different between the two groups. Treatment with irbesartan was associated with a significant decrease in the levels of all the parameters. Similar findings were observed in the atenolol group, except for factor XII and tissue factor pathway inhibitor levels, which were not significantly decreased in this group. The reduction, however, of fibrinogen, plasminogen activator inhibitor-1, and thrombomodulin was significantly greater in the irbesartan than in the atenolol group. In conclusion, the results indicated that, despite an equally controlled blood pressure, 6-month therapy with irbesartan was associated with a more favorable modification of hemostatic/fibrinolytic status than atenolol. (C) 2000 American Journal of Hypertension, Ltd